Showing results (71-80 of 85) with videos related to
Sort By:
Pageof 9
Movement Disorders : Official Journal of the Movement Disorder Society|January 26, 2019
Brain cholesterol metabolism and Parkinson's diseaseXuemei Huang, Nicholas W Sterling, Guangwei Du, et al.Viruses|September 23, 2022
Therapeutic Potential of 5'-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell CarcinomaEmily J Koubek, Jillian S Weissenrieder, Luz E Ortiz, et al.Oncoimmunology|September 20, 2018
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AMLLiru Wang, Bei Jia, David F Claxton, et al.Cancer Chemotherapy and Pharmacology|June 19, 2004
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 daysHoward H Bailey, George Wilding, Kendra D Tutsch, et al.Oncotarget|September 1, 2016
GBM-associated mutations and altered protein expression are more common in young patientsSherise D Ferguson, Joanne Xiu, Shiao-Pei Weathers, et al.Journal of Hematology & Oncology|June 21, 2017
Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemiaLiuluan Zhu, Yaxian Kong, Jianhong Zhang, et al.British Journal of Haematology|October 2, 2019
Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AMLChenchen Zhao, Bei Jia, Ming Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101Antonius A Miller, Daryl J Murry, Kouros Owzar, et al.Oncoimmunology|February 5, 2019
Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunityKathleen M Kokolus, Jeremy S Haley, Emily J Koubek, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2016
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple MyelomaNoopur S Raje, Edward A Faber, Paul G Richardson, et al.Pageof 9